ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Crescent Capital BDC (CCAP)
Crescent Capital BDC stock price today, ATLAS forecast and fair value
Financial Services · Asset Management · NASDAQ
$8.70▲ +0.46%
Prices as of Oct 26, 2026 · USD
Chance of rising in 1 month
52%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Crescent Capital BDC in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Crescent Capital BDC
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Crescent Capital BDC a 52% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $8.36 and $9.11; in 9 out of 10, between $7.75 and $9.83. Estimated annual volatility is 25%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $333M
- Dividend yield
- 46.90%
- 52-week high
- $15.18
- 52-week low
- $8.40
- Revenue (12 months)
- $156M
- Revenue growth (YoY)
- -43.2%
- Earnings growth (YoY)
- -53.3%
- Return on equity
- -0.5%
- Free cash flow (12 months)
- $49.7M
- Beta
- 0.57
What this means
ATLAS does not publish a fair value for CCAP right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks CCAP has traded between $8.40 and $15.18. Today it is 42.7% below that high and 4% above its low.
Its beta is 0.57: it tends to move less than the market.
About the company
Crescent Capital BDC Inc. is a business development company focused on providing debt financing to private U.S. middle-market companies.
Want to see everything about Crescent Capital BDC?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Crescent Capital BDC do?
Crescent Capital BDC Inc. is a business development company focused on providing debt financing to private U.S. middle-market companies.
What is the chance CCAP goes up next month?
52%: close to a coin flip. In half of the simulated outcomes, CCAP ends the month between $8.36 and $9.11.
How big is Crescent Capital BDC and what is its P/E ratio?
Crescent Capital BDC's market capitalization is $333M. We do not show a P/E because it has no positive earnings to base one on.
Does Crescent Capital BDC pay a dividend?
Yes. CCAP's current dividend yield is 46.90% at today's price ($8.70).
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer